May 14, 2025 – The United States FDA has granted accelerated approval to AbbVie’s Emrelis (telisotuzumab vedotin-tllv) for adults with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC). It is a c-Met directed antibody and microtubule inhibitor conjugate.
The FDA also approved the VENTANA MET (SP44) RxDx Assay (Roche Diagnostics). This test serves as a companion diagnostic to help detect c-Mer protein overexpression in patients with non-squamous NSCLC who might be eligible for treatment with Emrelis.
Emrelis belongs to a class of drugs called antibody-drug conjugate category. These therapies target only cancer cells without affecting healthy tissues. This makes antibody-drug conjugates like Emerlis ideal replacements for conventional chemotherapy.
Emrelis received approval for the treatment of a certain type of non-squamous non-small cell cancer (NSCLC). This approval applies to patients who had previously undergone other treatments, but the disease still spread to other body parts.
About 25% to 37% of patients with NSCLC exhibit high c-Met protein overexpression, as per the National Institutes of Health. Rising prevalence of this cancer type is expected to drive demand for non-small cell lung cancer treatments like Emrelis.
According to Coherent Market Insights (CMI), the global non-small cell lung cancer market is expected to expand from US$ 28.61 billion in 2025 to USD 54.38 Bn by 2032. Global demand for non-small cell lung cancer treatments will likely increase at a CAGR of 9.6% during the forecast period.
“FDA’s approval of AbbVie’s Emrelis marks a pivotal advancement in the treatment landscape for non-small cell lung cancer. It will offer a new ray of hope, particularly for patients with high c-Met protein overexpression. Being an antibody-drug conjugate, Emrelis offers a targeted therapeutic approach that may reduce systemic toxicity compared to traditional chemotherapy,” says a senior analyst at CMI.
Patients suffering from NSCLC are constantly seeking novel treatments with high efficacy and fewer side effects. Emrelis’ approval could offer a new therapeutic option that potentially improves outcomes while minimizing adverse effects.
The success of Emrelis could encourage other companies to increase their spending on research and development for developing antibody-drug conjugates. They will also focus on expediting the approval process to bring these therapies to market more quickly and gain a competitive edge.
Sources:
News Outlet: Reuters
U.S. Federal Agency: FDA
